Xcellerant backs hypertension genomics firm Geneticure with $1M as it builds Arizona lab
What's the deal? GeneticureDealroom has a profile for this one. Try Dealroom →, a precision-medicine diagnostics company, has raised $1 million in an early-stage round led by Xcellerant VenturesDealroom has a profile for this one. Try Dealroom →, a Scottsdale, Arizona venture firm. The company develops genetic tests to help guide treatment for high blood pressure.
What's the endgame? Geneticure's cheek-swab test analyses physiological pathways to estimate whether a patient will respond to renal denervation (RDN), an FDA-approved procedure for hypertension. It holds two U.S. patents and also sells a commercial test to guide medication choices.
Why now? The company will use the capital to advance clinical validation, refine reimbursement strategies, and prepare for a Series A round. It also plans to build a laboratory in Arizona to move operations closer to clinical partners and talent.
"Renal denervation is a game-changer, but the ability to identify the right candidates has been a critical missing link," said Mike Shufeldt, general partner at Xcellerant. CEO Scott Snyder said a local base "will help us scale effectively," adding that "Xcellerant brings more than just capital to the table."
The expansion: The Arizona lab extends Geneticure's footprint beyond its Minnesota base, and fits Xcellerant's regional strategy. The firm has built a healthtech and medtech portfolio and partnered with the Flinn FoundationDealroom has a profile for this one. Try Dealroom → to support Arizona bioscience.
What could go wrong? Geneticure's RDN responder work remains investigational and is not validated for routine clinical use. Its path to a larger Series A depends on clinical validation and reimbursement that are still unproven.
The signal: At $1 million, this is a modest round — sitting near the bottom of comparable deals by size. Its significance is as targeted early capital for a local precision-medicine company and part of a broader push to grow Arizona's early-stage bioscience sector, which includes the University of Arizona's Wildcat Philanthropic Seed Fund backing spinouts in 2026.
Read more: third-news.com
Image credit: Yuya Tamai
